LONDON, April 14 — Lilly’s brand value has skyrocketed by 108% since it entered the weight loss market in 2023, according to a new report from Brand Finance, a leading global brand valuation consultancy.
The pharmaceutical giant is now the second most valuable pharmaceutical brand worldwide, with a brand value of $8.0 billion. Novo Nordisk, a dominant player in weight loss and diabetes treatments, has also experienced substantial growth, with its brand value rising 130% since 2022.
Both companies have fueled their growth by combining the success of their treatments with strategic acquisitions, expanding their product pipelines and boosting their future growth prospects.
Meanwhile, Johnson & Johnson (J&J) has maintained its position as the most valuable pharmaceutical brand, increasing its brand value by 16% to reach $15.5 billion. J&J also holds the title of the strongest pharma brand, with a Brand Strength Index (BSI) score of 83.5 out of 100.
J&J’s strength is further supported by the lasting legacy of its consumer health division, which spun off as Kenvue in 2023. Despite this, the brand remains highly recognized across key markets. Bayer ranks as the second strongest pharmaceutical brand, with a BSI score of 82.2 out of 100.
“The top 25 most valuable brands in the pharmaceutical and medical device sectors have seen modest growth—1% and 5%, respectively—over the past year. While growth is steady, innovation remains a major driver. Breakthrough treatments like those from Novo Nordisk and Lilly have propelled both brands to new heights, with Lilly being the fastest-growing pharma brand among the top 25, increasing by 36% year on year,” said Brand Finance valuation director Hugo Hensley.
In contrast, the US healthcare services sector is under pressure, with nine of the ten most valuable brands experiencing declines. Brand Finance research indicates a drop in public sentiment, as increased scrutiny and regulatory challenges affect the reputation of major healthcare providers.
Medtronic has emerged as the most valuable medical device brand, with a 2% increase in brand value to $7.4 billion. This shift marks a change at the top of the rankings, as Fresenius, which held the top spot in 2024, saw its brand value fall by 5% to $7.3 billion.
Additionally, GE HealthCare has entered the rankings following its spin-off from General Electric, with a brand value of $3.1 billion.
UnitedHealthcare, which saw a 14% increase in brand value to $54.2 billion, is the only brand in the healthcare services sector to record growth in 2025. It also retains its position as the strongest brand in the sector, with a BSI score of 84.8 out of 100.
The recent murder of Brian Thompson, CEO of UnitedHealthcare’s insurance division, occurred after Brand Finance’s research was completed and did not impact this year’s results.
